The first diagnostic test to classify cancers by differences in microRNAs–small pieces of RNA that regulate genes–will soon be on the market. The test distinguishes two types of lung cancer and should help doctors tailor treatments to their patients’ needs. Scientists say that tests based on microRNA profiles could prove more sensitive and reliable than existing methods, whose accuracy depends heavily on the judgment of the people analyzing them.
Product: MicroRNA test for lung cancer
Cost: Comparable to that of other molecular tests for cancer, which are priced at around $3,000 to $3,500
Company: Rosetta Genomics
Other products in this section:
Couldn't make it to EmTech Next to meet experts in AI, Robotics and the Economy?Go behind the scenes and check out our video
A better way to measure magnetic fields could make fetal heart problems easier to detect
Nobody had been able to build a practical device that worked at room temperature–until now.
First evidence that amino acids formed soon after the Big Bang
A new measurement of chemical evolution suggests that amino acids filled the early universe some nine billion years before life emerged. That has important implications for understanding the origin of life and attempting to re-create it in the lab.
Algorithm matches human cardiologists in detecting heart attacks
Medical data tends to be messy and hard to annotate, which makes it hard for neural networks to learn from. But machine learning is beginning to make progress.